Ticagrelor
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ticagrelor |
| DrugBank ID | DB08816 |
| Brand Names (EU) | Brilique |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.97% |
Approved Indication (EMA)
Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event Brilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high ris
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | intracranial arteriosclerosis | 99.97% | DL |
| 2 | intermittent vascular claudication | 99.96% | DL |
| 3 | Monckeberg arteriosclerosis | 99.94% | DL |
| 4 | peripheral arterial disease | 99.91% | DL |
| 5 | peripheral vascular disease | 99.90% | DL |
| 6 | priapism | 99.75% | DL |
| 7 | ischemic disease | 99.64% | DL |
| 8 | May-Thurner syndrome | 99.55% | DL |
| 9 | livedo reticularis | 99.53% | DL |
| 10 | mesenteric vascular occlusion | 99.50% | DL |
| 11 | vascular ectasia | 99.47% | DL |
| 12 | angiodysplasia | 99.28% | DL |
| 13 | venous thromboembolism | 99.27% | DL |
| 14 | fibrocartilaginous embolism | 99.27% | DL |
| 15 | non-inflammatory vasculopathy | 99.13% | DL |
| 16 | erythromelalgia | 99.10% | DL |
| 17 | kyphoscoliotic heart disease | 99.04% | DL |
| 18 | congenital renal artery stenosis | 99.04% | DL |
| 19 | Prinzmetal angina | 98.75% | DL |
| 20 | vascular insufficiency disorder | 98.60% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.